ABSCI CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ABSCI CORP (ABSI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $6.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-11
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $5.55M, a 8435.38% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $782.00K, a 50.51% decline year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $661.00K, a 32.20% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $93.00K, a 92.00% decline year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $2.40M, a 41.43% decline from fiscal 2024.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $4.10M, a 998.12% increase from fiscal 2023.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $373.00K, a 82.24% decline from fiscal 2022.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $2.10M, a 50.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $6.33M 10-Q · filed 2026-08-11 | $6.99M derived: sum of 3 quarters · filed 2026-08-11 | $7.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $782.00K 10-Q · filed 2026-05-07 | $1.44M derived: sum of 2 quarters · filed 2026-05-07 | $1.54M derived: sum of 3 quarters · filed 2026-05-07 | $1.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $661.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $754.00K derived: sum of 2 quarters · filed 2026-03-24 | $819.00K derived: sum of 3 quarters · filed 2026-03-24 | $2.40M 10-K · filed 2026-03-24 |
| 2025-09-30 | $93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $158.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.74M 10-Q · filed 2025-11-12 | $2.24M derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.65M 10-Q · filed 2025-08-12 | $2.15M derived: sum of 3 quarters · filed 2025-08-12 | $3.31M derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | $1.58M 10-Q · filed 2025-05-13 | $2.08M derived: sum of 2 quarters · filed 2025-05-13 | $3.24M derived: sum of 3 quarters · filed 2025-05-13 | $4.44M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.66M derived: sum of 2 quarters · filed 2025-03-18 | $2.86M derived: sum of 3 quarters · filed 2025-03-18 | $4.10M 10-K · filed 2025-03-18 |
| 2024-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.36M derived: sum of 2 quarters · filed 2024-11-12 | $3.60M 10-Q · filed 2024-11-12 | $3.72M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.43M 10-Q · filed 2024-08-14 | $2.56M derived: sum of 3 quarters · filed 2024-08-14 | $2.72M derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | $1.23M 10-Q · filed 2024-05-14 | $1.36M derived: sum of 2 quarters · filed 2024-05-14 | $1.52M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2023-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $287.00K derived: sum of 2 quarters · filed 2024-03-21 | $373.00K 10-K · filed 2024-03-21 | |
| 2023-09-30 | $164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $250.00K 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $86.00K 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $300.00K derived: sum of 2 quarters · filed 2023-03-30 | $900.00K derived: sum of 3 quarters · filed 2023-03-30 | $2.10M 10-K · filed 2023-03-30 |
| 2022-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $800.00K derived: sum of 2 quarters · filed 2022-11-09 | $2.00M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.80M 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $1.20M 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $1.40M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |